Mindray × Tencent: Global First AI Foundation Model for Medical Technical Services
On August 10, Mindray Medical and Tencent Cloud launched what they describe as the world’s first medical technology service LLM. Built on Mindray’s global service network and knowledge base, the AI expert provides 24/7 technical support for hospital engineers and frontline healthcare professionals. Covering 190+ countries and regions and 100+ languages, the model integrates 5,000+ clinical knowledge items and 500+ device-related datasets, with a reported 99% accuracy on key questions and support for more than 1,700 professional queries per day.
Powered by Tencent Cloud’s Agent Development Platform (ADP), DeepSeek and RAG technology, the system transforms Mindray’s technical documents and service expertise into a continuously updated digital knowledge hub. Beyond improving response efficiency, the initiative marks a broader shift in medical device services—from human-led support toward AI-enabled, standardized and globally scalable services, with potential applications in remote support, predictive maintenance and intelligent training.
Sansure Invests in AI Drug Discovery Company
On August 5, Beijing Zheyuan Technology announced nearly RMB 200 million in Series A2 financing, led by Sansure Biotech and its industry fund, with existing investor Casstar and new investors including Zhangjiang Science Investment participating. The funding will support the continued development of Zheyuan’s “Life World Model” and AI4S platform, covering genomic, signaling pathway, virtual cell and disease models, while accelerating AI agents, experimental validation, innovative drug pipelines and virtual clinical trials.
Focused on “AI4S + disease,” Zheyuan uses digital twins of biological systems to model diseases across multiple scales, from genes and cells to disease microenvironments and patient responses. Its platform supports D2P (Disease to Product) and T2I (Target to Indication) solutions for pharmaceutical companies, while its proprietary Class I drug PR00012 has entered Phase I clinical trials. Sansure’s investment marks a deeper strategic move into AI-driven drug discovery, with both sides planning to expand collaboration across disease-focused research and pharmaceutical innovation.
Snibe Launches AI-Powered iXLAB Platform to Enhance Clinical Decision-Making
Snibe Diagnostic has launched its iXLAB Smart Diagnosis and Treatment Decision-Making Platform, designed to integrate laboratory results, patient records, health questionnaires and historical data across the “prevention, screening, diagnosis, treatment and rehabilitation” continuum. The platform uses AI to structure and interpret laboratory reports, analyze trends and correlations, assess disease risk and identify high-risk populations, while providing clinicians with a consolidated view of patient information to support follow-up and long-term health management.
From an industry perspective, the launch reflects the growing shift of IVD companies from “testing and reporting” toward data-driven clinical support. Rather than simply increasing testing efficiency, AI platforms such as iXLAB seek to connect fragmented laboratory and clinical data and translate test results into actionable insights. The effectiveness of this model will ultimately depend on data quality, clinical validation, integration with existing healthcare systems and the reliability of AI-generated recommendations.
Tellgen Corporation Officially Enters the Alzheimer’s Blood Testing Market
Shanghai Tellgen orporationand its subsidiary Shanghai Maishi Biotechnology have recently received acceptance from the Shanghai Medical Products Administration for several medical device registration applications. Four products are intended for the auxiliary diagnosis of Alzheimer’s disease (AD), covering key blood biomarkers including the Aβ1-42/Aβ1-40 ratio, p-Tau181 and p-Tau217. The company has also submitted products for hormone-related disorders and fat-soluble vitamin assessment, further expanding beyond its core oncology testing portfolio.
The products are developed on Tellgen’s chemiluminescence platform and Maishi’s LC-MS/MS platform, marking the company’s expansion into AD and metabolic testing. The applications are currently at the registration acceptance stage and still require technical review, administrative approval and final registration approval.
AmoyDx Secures Two MET Companion Diagnostic Approvals in Japan
Amoy Diagnostics has received two new approvals from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its multi-target lung cancer PCR testing product, AmoyDx Pan Lung Cancer PCR Panel. The product is now approved as a companion diagnostic for Novartis’ capmatinib and Haisco Pharmaceutical’s glumetinib, supporting treatment selection for locally advanced or metastatic NSCLC patients with MET exon 14 skipping mutations.
The approvals further expand AmoyDx’s companion diagnostic portfolio in Japan. To date, the product has received approval covering seven targets—including EGFR, ALK, ROS1, BRAF, MET, KRAS G12C and RET—to guide the clinical use of 16 targeted therapies for NSCLC. The progress also highlights the growing role of molecular diagnostics in matching patients with targeted oncology treatments.
